Cheung Gemmy Chui Ming, Lai Timothy Y Y, Gomi Fumi, Ruamviboonsuk Paisan, Koh Adrian, Lee Won Ki
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
Duke-NUS Medical School, National University of Singapore, Singapore.
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):527-534. doi: 10.22608/APO.2017260. Epub 2017 Oct 3.
Anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of neovascular age-related macular degeneration (AMD). This review will summarize the current evidence of anti-VEGF therapy in neovascular AMD, including subtypes of retinal angiomatous proliferation and polypoidal choroidal vasculopathy (PCV). Importantly, 2 large multicenter randomized clinical trials evaluating the safety and efficacy of anti-VEGF monotherapy and combination with photodynamic therapy (PDT) have recently reported initial first-year outcomes. In this review, we summarize the latest updates in the efficacy and safety of anti-VEGF monotherapy and combination with PDT in common lesion subtypes. Remaining gaps in current understanding are highlighted where further research is needed.
抗血管内皮生长因子（anti-VEGF）疗法彻底改变了新生血管性年龄相关性黄斑变性（AMD）的治疗方式。本综述将总结抗VEGF疗法在新生血管性AMD中的现有证据，包括视网膜血管瘤样增殖和息肉状脉络膜血管病变（PCV）的亚型。重要的是，两项评估抗VEGF单药治疗以及与光动力疗法（PDT）联合治疗的安全性和有效性的大型多中心随机临床试验最近报告了第一年的初步结果。在本综述中，我们总结了抗VEGF单药治疗以及与PDT联合治疗在常见病变亚型中的疗效和安全性的最新进展。文中突出了当前认识中仍存在的差距，表明需要进一步开展研究。
